September 20, 2019 12:52 PM EDTUpdated September 23, 10:41 AM

Here comes the oral GLP-1 drug for diabetes — and Novo Nordisk wants to price Rybelsus 'at a similar level as Ozempic'

Amber Tong

Novo Nordisk’s priority review voucher on oral semaglutide has paid off. The FDA approval for the GLP-1 drug hit late Friday morning, around six months after the NDA filing.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Here comes the oral GLP-1 drug for diabetes — and Novo Nordisk wants to price Rybelsus 'at a similar level as Ozempic'

Amber Tong

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

FDA gives AbbVie accelerated approval for antibody-drug conjugate in lung cancer

RFK Jr. defends HHS staff cuts, reorganization plans in House, Senate hearings

AbbVie doubles down on siRNA with $335M upfront bet on ADARx

GSK to pay $1.2B upfront to snag Boston Pharma’s mid-stage MASH hope

RFK Jr. says his opinions of vaccines are ‘irrelevant.’ Former FDA chief Califf disagrees

Novo turns to Septerna for oral obesity medicines in deal worth up to $2.2B

Here comes the oral GLP-1 drug for di­a­betes — and No­vo Nordisk wants to price Ry­bel­sus 'at a sim­i­lar lev­el as Ozem­pic'

Sign up to read this article for free.

more like this

ImmunityBio, Inc.

Remote

Here comes the oral GLP-1 drug for diabetes — and Novo Nordisk wants to price Rybelsus 'at a similar level as Ozempic'